905454-58-2

Basic information

• Product Name: (1’S,2S)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane
• Synonyms: (1’S,2S)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane;(1’S,2R)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane;(1S)-1-[(2S)-6-Fluoro-3,4-dihydro-2H-1-benzopyran-2-yl]-1,2-ethanediol 2-(4-Methylbenzenesulfonate)
• CAS NO: 905454-58-2
• Molecular Formula: C₁₈H₁₉FO₅S
• Molecular Weight: 366.4038632
• Product Categories: Intermediates & Fine Chemicals. Sulfur & Selenium Compounds;Aromatics;Pharmaceuticals;Chiral Reagents;Intermediates & Fine Chemicals;Sulfur & Selenium Compounds
• Mol File: 905454-58-2.mol

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Dichloromethane, Methanol
• CAS DataBase Reference: (1’S,2S)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane(CAS DataBase Reference)
• NIST Chemistry Reference: (1’S,2S)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane(905454-58-2)
• EPA Substance Registry System: (1’S,2S)-2-(2’-Tosyl-1’,2’-dihydroxyethyl)-6-fluorochromane(905454-58-2)

Safety Data

• Hazardous Substances Data: 905454-58-2(Hazardous Substances Data)

Usage

Chemical Properties

Pale Brown Solid

Upstream product

• 905454-57-1 1-[6-fluoro-(2S)-3,4-dihydro-2H-benzopyran-2-yl]-(1S)-1,2-ethylene glycol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 129050-23-3 (2S)-6-fluoro-2-[(2S)-oxiran-2-yl]-3,4-dihydro-2H-chromene 

Relevant articles and documents

Synthesis of intermediate compound and [...] (by machine translation)

Synthesis of intermediate compounds [a] and [...]. [Solution] a [...], asymmetric epoxidation, sulfonyl halide in the presence of base catalyst by sulfonation, alkylation of amines, such as synthesized by a series of cross-coupling reaction. [Effect] [...] important from the viewpoint of pharmacological value, high efficiency, low cost, and which meets the requirements of industrial, optical isomers may be prepared [...] and develop a method, which is very economical in social benefit. [Drawing] no (by machine translation)

NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF

The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.

Nebivolol synthetic method and intermediate compounds of the

The present invention relates to a synthesis method and an intermediate compound of nebivolol. Specifically the invention relates to the method for synthesizing the nebivolol, the intermediate compound of the nebivolol, and a method for preparing the intermediate compound.

A process for the preparation of nebivolol and wherein the intermediate compound

The invention discloses a preparation method of nebivolol used for preparing medicines for treating hypertension of slight or medium degrees, and an intermediate compound. The preparation method comprises the following steps: taking 6-fluoro-2-(1-hydroxy-2-paratoluensulfonyl oxygroup-ethyl)-3,4-dihydrobenzopyrans as an initial raw material, introducing amino, then coupling with 6- fluoro-3,4-dihydro-2-epoxy ethyl-2H-1-benzopyran, and preparing (S,R,R,R) and (R,S,S,S)-nebivolol. Compared with a prior art, the preparation method has the advantages of novel design, simple operation and high yield, the usage of hazardous reagent such as ssodium azide and sodium hydride can be avoided, a column chromatography purifying method is avoided, so that the preparation method conforms to industrial production.

Hydroxylated nebivolol metabolites

Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.